title: [A randomized controlled study on the impact of pharmacoeducation on a French patient population with schizophrenic and schizoaffective disorders].
abstract: OBJECTIVE
  To evaluate the impact of a pharmacoeducation module both on hospital stay and on clinical and functional state in a French patient population with schizophrenic and schizoaffective disorders.
  
  
  METHODS
  After inclusion, 82 patients were randomly distributed in 2 groups, one group receiving the pharmacoeducation module and the other to be a control group. Data on the number of hospital stays and emergency visits, and the type of medication received, were compiled. Patients were evaluated with the Positive and Negative Syndrome Scale, Clinical Global Impression Scale, Barnes Akathisia Scale, Simpson-Angus Scale, Quality of Life Scale, and Global Assessment of Functioning; data were gathered at baseline, then each year for 2 years.
  
  
  RESULTS
  Among the 72 analyzed patients, those receiving pharmacoeducation had significantly lower total hospital stays, forced hospital stays, and emergency visits, compared with the control group patients. They also had more improvement in their symptomatology, autonomy, and quality of life. They presented less akathisia and less medication intake.
  
  
  CONCLUSIONS
  Pharmacoeducation can reduce the hospital stays of patients with schizophrenia and schizoaffective disorders, as well as improve their clinical and functional state, likely through better compliance.
authors.affiliation: Pôle universitaire de psychiatrie adultes, Centre hospitalier universitaire Sainte Marguerite, Marseille, France.
authors.forename: Murièle
authors.initials: M
authors.lastname: Maurel
authors.forename: Delphine
authors.initials: D
authors.lastname: Drai
authors.forename: Arthur
authors.initials: A
authors.lastname: Kaladjian
authors.forename: Vanessa
authors.initials: V
authors.lastname: Pauly
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Azorin
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005602:France; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D057187:Independent Living; D007902:Length of Stay / Q000706:statistics & numerical data; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D010353:Patient Education as Topic; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D011594:Psychometrics; D011618:Psychotic Disorders / Q000188:drug therapy*; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D011788:Quality of Life; D012559:Schizophrenia / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D011619:Psychotropic Drugs